Highlights Creative Medical Technology Holdings, Inc. Other OTC

Equities

CELZ

US22529Y2000

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Creative Medical Successfully Generated Human Ipsc-Derived Islet Cells That Produce Human Insulin	24/06	RE
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin	24/06	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05	CI
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	23/03	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/03	CI
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201	07/03	DJ
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access	07/03	CI
Creative Medical Shares Rally Premarket on FDA Orphan Designation	06/03	DJ
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony	06/03	MT
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem	20/12	CI
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	15/11	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain	10/23/10	CI
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem? (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain	19/23/19	CI
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	12/23/12	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Creative Medical Technology Holdings, Inc. announces an Equity Buyback for $2 million worth of its shares.	12/23/12	CI
Creative Medical Technology Holdings, Inc. authorizes a Buyback Plan.	12/23/12	CI
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform	31/23/31	CI
Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development	22/23/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Creative Medical Technology Holdings, Inc. Other OTC

Equities

CELZ

US22529Y2000

Highlights

Filters